尊敬的生物基领域的可持续先锋们 ： 扫描图片二维码报名 2026 DT新叶奖 · 邀请函 新年好！ 截止目前，已有 近50家 上市和代表性企业， 共60余份 新品报名参选2026DT新叶奖， 现公布四大奖项参选企业名单与参选产品 。 我们诚挚欢迎更多优秀企业积极报名参与，共同展现生物基领域的创新力量！ 报名截止时间：3月13日 2026第4届DT新叶奖（DT New Leaf Award）是由DT新材料、生物基能源与材料联合举办的全球化、专业性、综合性奖项，专注于生物基领域创新，被誉 为"生物基行业的奥斯卡"。 "新叶"，寓意蓬勃生机与可持续创新活力。DT新材料以此命名，旨在发掘生物基行业的先锋力量 —— 以可再生生物质为原料，用绿色技术突破传统局 限，驱动行业焕发低碳新生机，引领可持续发展新征程。 生物基能源与材料 Bio-based 2026 会务组 ▶ 获奖公布& 颁奖典礼 #第11届生物基大会 开幕式（5月21日，上海富悦大酒店） ⭕ 新叶奖 官网 一、 参选企业与产品 创新 材料奖 发掘生物基关键平台化合物和创新材料， 鼓励从"0"到"1"的源头创新 | 企业名称 | 参选产品 | | --- | ...

Consumption Trends - The emotional economy market in China is expected to exceed 20 trillion yuan in 2024, with a projected CAGR of 14% from 2025 to 2029[3][60]. - The beauty consumption market is projected to reach nearly 370 billion yuan by 2025, with the retail sales of cosmetics in China estimated at 465.3 billion yuan in 2025, reflecting a year-on-year growth of 5.1%[5][51]. - The health food market is anticipated to reach 720.3 billion yuan by 2029, driven by increasing health awareness and aging population[5]. Policy and Market Dynamics - The Chinese government has prioritized boosting consumption as a key task for 2025, with policies supporting consumption upgrades and equipment renewal[5][9]. - Changing consumer behavior emphasizes emotional value, health, and personalized consumption, indicating a shift towards emotional and social fulfillment in purchasing decisions[5][9]. Key Industry Insights - The maternal and infant food market is projected to reach approximately 55.91 billion yuan in 2024, with the number of maternal and infant chain stores increasing from 21,000 in 2019 to 32,000 in 2024[5]. - The pet economy is expected to grow significantly, with the market size reaching 701.3 billion yuan in 2024, reflecting an 18% year-on-year increase[58]. Investment Opportunities - Companies in the North Exchange related to beauty consumption include Jinbo Biological, Bawei Co., and Vicky Technology, which are positioned to benefit from the ongoing growth in the beauty sector[5][52]. - The health food sector includes leading brands like Kangbiter and Yizhi Konjac, which are well-placed to capitalize on the rising demand for health-oriented products[5].

Investment Rating - The report indicates a positive outlook for the consumer service industry on the Beijing Stock Exchange, highlighting investment opportunities driven by policy support and emerging consumption trends [1][22]. Core Insights - The consumer market in China has shown signs of recovery, with the Consumer Price Index (CPI) reaching a year-high growth of 0.7% in November 2025, while the Producer Price Index (PPI) has shown marginal improvement [2][5]. - The report identifies several consumption hotspots, including policy-driven consumption, emotional economy, health consumption, silver economy, national trend economy, and experience economy [2][12]. - The median market capitalization growth for 41 consumer service companies on the Beijing Stock Exchange was +30.92% in 2025, with 36 companies (88%) experiencing an increase [13][15]. - The median Price-to-Earnings (PE) ratio for consumer service companies was reported at 46.3x, indicating relatively low valuations and potential investment opportunities in 2026 [19][22]. Summary by Sections Domestic Consumption Market Trends - In 2025, the CPI showed a gradual recovery, with November's growth at 0.7%, marking the highest point of the year [5]. - The retail sales growth varied across categories, with strong performance in communication equipment, home appliances, and furniture, while traditional consumer goods like tobacco, clothing, and beverages lagged [6][8]. Market Performance - The median market capitalization change for consumer service stocks was -2.39% in the last week of December 2025, with notable performers including Thunder God Technology (+10.10%) and Vision Intelligence (+3.14%) [12][15]. - The overall market capitalization for consumer service companies decreased from 115.18 billion to 109.71 billion yuan, with a median market cap drop from 1.906 billion to 1.873 billion yuan [12][15]. Valuation Metrics - The median PE ratio for the broader consumer industry was reported at 49.3x, reflecting a slight decrease from previous periods [19][22]. - Specific sectors such as food and beverage, and agriculture showed median PE ratios of 49.5x, indicating stable valuations despite market fluctuations [19][22]. Company Highlights - Key companies in the consumer service sector include Gai Shi Food, Oufu Egg Industry, and Biowave, with significant market capitalization growth and diverse product offerings [22][26]. - The report emphasizes the potential of companies in the pet food, cosmetics, and agricultural sectors, with a robust pipeline of companies poised for listing on the Beijing Stock Exchange [22][27].

Core Viewpoint - The article highlights the New Leaf Award, a global and comprehensive award focused on innovation in the bio-based sector, aimed at discovering, showcasing, and recognizing outstanding products and companies in the bio-based industry, often referred to as the "Oscar" of the bio-based sector [2]. Group 1: Award Information - The New Leaf Award includes categories such as Innovation Materials Award, Innovation Applications Award, Most Commercially Valuable Award, and Innovative Industry Solutions Award [3]. - The deadline for the fourth selection activity is March 13, 2026 [8]. Group 2: Company Profile - Yuan Yi (Tianjin) Biotechnology Co., Ltd. is a leading company in synthetic biology solutions, competing for the 2026 New Leaf Awards in the "Innovation Materials Award" and "Most Commercially Valuable Award" categories [3]. Group 3: Product Details - The company offers recombinant humanized collagen, which is 100% homologous to human collagen sequences, featuring high activity, low allergenicity, and the ability to support large-scale production and precise applications in various scenarios [9]. - The product is advantageous for promoting cell adhesion and enhancing cell repair functions, with high purity and low allergen rates, and it does not pose risks of endotoxin contamination [10]. Group 4: Applications and Benefits - In the medical aesthetics field, the heat-resistant properties of the gel prevent dissolution due to body temperature, ensuring longer retention at target sites, thus improving tissue repair and anti-aging effects [10]. - In skincare products, the heat-resistant gel can withstand emulsification temperatures above 80°C, preventing loss of activity during production and expanding the range of collagen skincare products [10]. - In the biomedical field, the heat-resistant collagen gel can endure high temperatures during sterilization and provide sustained moisture and repair barriers for high-temperature wounds, enhancing clinical treatment efficiency [10]. Group 5: Product Range - Yuan Yi Biotechnology has developed various types of collagen, including 18 different molecular weights, allowing for tailored solutions to multiple issues, achieving a self-research, self-production, and self-sales closed loop [10].

Core Viewpoint - The article discusses the shifting landscape of wealth in China over the past decade, highlighting the rise of new wealthy individuals in the "emotional" economy, contrasting with the decline of traditional real estate tycoons [4][6]. Group 1: New Wealth Creation - The top new wealthy individuals in 2025 include Xu Gaoming and Xu Dongbo from Laopu Gold, with a wealth of 69.5 billion yuan, and Li Qibin and Qi Yan from Card Game, with 60 billion yuan [6]. - Companies like Pop Mart and Laopu Gold reported revenue and net profit growth exceeding 200% year-on-year in their latest financial reports [6][9]. - Card Game's revenue is projected to surpass 10 billion yuan in 2024, with a net profit margin exceeding 40%, outperforming Pop Mart [6]. Group 2: Emotional Economy - The rise of brands like milk tea chains has created a new class of wealthy individuals, emphasizing emotional connection and cultural identity over mere product functionality [9]. - The article notes a significant shift from high-tech internet and manufacturing wealth creation in 2015 to emotional-driven businesses in 2025 [9][10]. Group 3: Investment Challenges - Many of the new wealthy individuals faced initial skepticism from major investment firms, which underestimated their potential before they achieved significant financial success [10][11]. - For instance, Pop Mart's founder struggled to secure funding until a key investor provided crucial support, leading to the brand's eventual success [10]. Group 4: Female Entrepreneurs - The article highlights the increasing presence of female entrepreneurs on the wealth list, with 22.4% of the total being women, many of whom are first-generation wealth creators [12][15]. - Notable female figures include Zong Fuli, who became the first female billionaire in the beverage industry, and Zhong Huijuan, who emerged as a new female billionaire in the pharmaceutical sector [15][16]. Group 5: Decline of Real Estate Tycoons - The article notes a significant decline in the representation of real estate tycoons on the wealth list, dropping from 30% to just 10% over the past decade [25][28]. - High-profile figures like Wang Jianlin and Xu Jiayin have fallen from grace due to financial struggles and legal issues, reflecting the broader challenges facing the real estate sector [28][29]. Group 6: Market Dynamics - The article discusses the changing dynamics in the market, with traditional brands in the apparel sector facing difficulties adapting to new consumer preferences and competition from emerging brands [30][32]. - Companies like Meisibangwei and others have struggled with financial losses and are attempting to pivot their business models to survive in a competitive landscape [30].

Core Viewpoint - The company has established a fully integrated production system for three cosmetic raw materials: hyaluronic acid, collagen, and royal jelly acid, with significant production capacities for each [1]. Group 1: Production Capacity - The annual production capacity for hyaluronic acid is 420 tons [1]. - The company has built a complete production base for recombinant human collagen, enabling a full industry chain from core raw material research and production to end cosmetic manufacturing [1].

Group 1: Battery Industry - Better Ray has been actively involved in the solid-state battery sector for over a decade, focusing on core materials for both semi-solid and all-solid batteries [4] - The company has developed a complete material system for solid-state batteries, including high-nickel cathodes, silicon anodes, lithium metal anodes, and solid electrolytes [4] - Better Ray's solid electrolyte research encompasses three directions: oxides, polymers, and sulfides, with successful small-scale applications in semi-solid batteries [4] Group 2: Biotechnology Industry - Jinbo Bio, recognized as the "first stock in medical beauty" on the Beijing Stock Exchange, holds a leading position in the field of recombinant humanized collagen, being the only company with a Class III medical device registration certificate for this product [5] - The company has maintained its technological advantage for over four years since obtaining its first registration certificate in 2021 and plans to increase R&D investment in original innovation [5] - Jinbo Bio is conducting clinical pre-experimental research on the application potential of recombinant humanized collagen in tumor treatment, specifically for breast cancer and endometrial cancer [7] Group 3: Computing Power Industry - Parallel Technology has not established a business cooperation with DeepSeek regarding computing power services, despite the growing interest in AI large models and related technologies [8][10] - The company positions itself as a provider of computing power and operational services, serving clients in AI, high-end manufacturing, and various research-driven technology enterprises [8] - Parallel Technology is actively promoting computing power services based on domestic computing chips and has integrated various types of domestic chip resources into its platform [10]

Core Insights - Dongxing Medical (301290) reported a revenue of 284 million yuan for the first three quarters of 2025, a year-on-year decline of 10.21%, with a net profit attributable to shareholders of -70 million yuan, down 263% year-on-year, primarily due to a goodwill impairment loss of approximately 100 million yuan recognized in the third quarter [1] Group 1: Business Performance - The company focuses on surgical medical devices, particularly in the field of anastomosis devices, and has two main business segments: surgical instruments represented by anastomosis devices and surgical equipment represented by operating tables and shadowless lamps [1] - In the anastomosis device sector, Dongxing Medical has emphasized the electric anastomosis device, achieving over 130% year-on-year revenue growth in 2024 [1] - The company has obtained a Class III medical device registration certificate for its self-developed fully electric laparoscopic anastomosis device, further solidifying its market position [1] Group 2: Market Trends - Industry data indicates that the anastomosis device market in China is expected to grow from 9.82 billion yuan in 2024 to 16.67 billion yuan by 2030, with electric laparoscopic anastomosis devices being a major growth driver, projected to have a compound annual growth rate of 16% during this period [1] Group 3: Strategic Initiatives - Dongxing Medical is actively expanding into synthetic biology by collaborating with research institutions such as Changzhou University and Shanghai Jiao Tong University to develop high-tech barrier materials like recombinant humanized collagen and mussel adhesive protein, aiming to launch innovative medical consumables for hemostasis and scar repair [2] - The company announced a significant advancement in its platform strategy by planning to acquire 90% of Wuhan Yijiaobao, which will allow it to enter the high-end orthopedic market and extend its industrial chain in surgical medical devices [3] - The acquisition is expected to accelerate the commercialization of synthetic biological materials and enhance the company's platform development [3]

Core Viewpoint - The core viewpoint of the article is that Jinbo Biotechnology, led by Chairman Yang Xia, is pioneering the industrialization of recombinant human collagen through original innovation, focusing on the development of medical products and cosmetics using this innovative material [4][6]. Group 1: Original Innovation - Jinbo Biotechnology's collagen, known as type III recombinant human collagen, is developed through original innovation, creating a complete production and sales loop [4][6]. - The company has been dedicated to two main areas: life materials based on recombinant human collagen and antiviral products represented by HPV biological proteins [6][9]. Group 2: Technological Breakthroughs - In 2025, Jinbo Biotechnology received approval for the world's first injectable recombinant type III human collagen gel, produced using self-assembly and self-crosslinking technology, which offers dual functions of filling and repairing against aging [8][10]. - The new product significantly enhances the safety of clinical filling materials and introduces innovative manufacturing methods and mechanisms of action compared to traditional fillers [8][10]. Group 3: Product Development and Applications - Type III collagen is primarily found in infants, and adults typically lack this type due to its loss over time, making it a strategic choice for the company [9]. - Jinbo Biotechnology has achieved three major breakthroughs: improving the safety of clinical filling materials, innovating manufacturing methods through AI-driven synthetic biology, and enhancing the mechanism of action for tissue repair and regeneration [10].

Summary of Key Points from the Conference Call Industry Overview - The Chinese medical aesthetics market has a penetration rate significantly lower than developed countries like the US, Japan, and South Korea, indicating substantial growth potential, especially in the light medical aesthetics sector [1][3] - The medical aesthetics industry is transitioning from chaotic growth to steady expansion, with an expected annual compound growth rate of 15% over the next few years [1][5] - The market for hyaluronic acid has seen a notable shift, with domestic brands rapidly increasing their market share, surpassing foreign brands, and driving the popularization of light medical aesthetics through competitive pricing [1][9] - The botulinum toxin market is projected to maintain a nearly 20% year-on-year growth rate, with market size expected to continue expanding [1][10] Market Dynamics - The regenerative materials market is competitive, with companies vying for market share through technological differentiation and customer segmentation, impacting the high-end hyaluronic acid market [1][12] - Recombinant humanized collagen is gaining traction in the light medical aesthetics market due to its structural advantages and safety, likely to further increase its market share [1][24] Market Size and Comparison - The Chinese medical aesthetics market has reached a scale of over 100 billion RMB, but still has significant room for growth compared to developed countries, with treatment rates per thousand people being only 1/4 of South Korea, 1/3 of the US, and 80% of Japan [3][4] - The light medical aesthetics market in 2021 was dominated by hyaluronic acid (51%) and botulinum toxin (33%), with recombinant humanized collagen accounting for approximately 6.5% of the market [23] Competitive Landscape - The competition in the hyaluronic acid market has shifted, with domestic brands capturing a significant share by offering lower prices compared to international brands [9][8] - The botulinum toxin market features products from various companies, with the core of market share differentiation relying on the capabilities of sales teams [10][11] Technological Innovations - The development of recombinant humanized collagen is seen as a key driver for the growth of the light medical aesthetics market, with expectations of increasing penetration rates from 6.5% in 2024 to 10% by 2027 [23] - Companies like Jinbo Biotechnology are leading in recombinant humanized preparation technology, having developed innovative injection-grade implants and continuously working on new products [29][30] Consumer Preferences - Consumer preferences vary by region, with American and Brazilian consumers favoring shaping procedures, while Asian consumers prioritize skin improvement and anti-aging effects [4] - The demand for regenerative materials reflects changing aesthetic values and a strong desire for natural and long-lasting anti-aging effects [12][13] Challenges and Opportunities - The collagen market in China is still developing, with a relatively limited range of products available, primarily dominated by imported products [25] - The historical challenges faced by collagen injectables, such as safety concerns and cost-effectiveness, have hindered rapid market growth compared to alternatives like hyaluronic acid [26] Conclusion - The medical aesthetics industry in China is poised for significant growth, driven by technological advancements, changing consumer preferences, and increasing market penetration of domestic brands. The focus on safety and efficacy in new product development will be crucial for sustaining this growth trajectory [1][24][29]